Introduction
============

Chemokines, with molecular weights in the range of 8 to 12 kDa, consist of about 50 small peptides in this superfamily ([@B113]). These widely expressed chemoattractant cytokines play an important role in regulating cell traffic processes ([@B15]). Subsequently their role is extended to other pathological and physiological conditions including angiogenesis, hematopoiesis, atherosclerosis, and cancer ([@B114]). According to the conserved cysteine residues from N-terminal, chemokine receptors can be classified into four subfamilies: (CXC, CC, CX3C, and C). Furthermore, the conserved ELR-motif is shared by some members of CXC-chemokines which exert angiogenic effects while those lacking ELR-motif are angiostatic ([@B124]). Chemokine receptors can also be classified based on their functions: homeostatic and inflammatory, or both. The constitutively expressed homeostatic chemokines play a key role not only in development but also in maintenance of immune systems, whereas inflammatory chemokines are induced when the relevant cells are stimulated ([@B136]).

CXCR7 is a seven transmembrane-spanning receptor. It has been re-named to ACKR3, implying it belongs to the atypical chemokine receptors (ACKRs) family. Most ACKRs lack functional domains for G~i~ protein coupling and signaling ([@B4]). The gene sequence of CXCR7 remains highly conserved among humans, dogs, mice, and rats ([@B82]). Originally it was cloned from a dog thyroid and named RDC-1 ([@B81]). In 2005, considering the similarity of its structure to CXC receptors, it was renamed CXCR7 according to chemokine receptor nomenclature ([@B7]; [@B47]). The gene of human CXCR7 is located on the region of 2q37.3 whereas in mice it is at 55.6 cM in the chromosome ([@B54]). Although CXCR7 encodes two exons, only the last exon is the solely translated coding region ([@B14]). Originally CXCR7 was considered as a receptor for calcitonin gene-related peptide (CGRP1) and vasoactive intestinal peptide (VIP) but studies have not been able to prove this ([@B25]; [@B93]). Unlike typical GPCRs, CXCR7 was shown not coupled with G~i~ proteins. Most chemokine receptors share a conserved motif DRYLAIV at the N-terminus of the second intracellular loop which is critical for calcium signaling and Gi protein coupling. The CXCR7 sequence is altered to DRYLSIT (A to S and V to T) and this structural difference was considered the reason on why CXCR7 is unable to induce cell signaling transduction through Gi proteins ([@B47]). At this point, how CXCR7 mediates activation of intracellular pathways remains controversial. Some studies have indicated that CXCR7 is a scavenger or decoy receptor which does not couple to Gi-proteins ([@B9]; [@B70]). Other evidence suggests that CXCR7 physically associated with CXCR4, leading to a change of CXCR4 signaling and cellular functions ([@B77]; [@B33]). In addition, a few studies demonstrate that CXCR7 can independently induce cell signaling via β-arrestin in certain cell lines ([@B111]; [@B22]). Interestingly, as of now, only in astrocytes, it was shown that CXCR7 was able to couple with Gi/o proteins and induced cell signaling ([@B105]). None of these studies is conclusive, however. This is particular true, because CXCR7 often are co-expressed with CXCR4 in the same cells and full deletion of either receptor *in vitro* or *in vivo* are not warranted. Thus, many of the cellular functions including cell migration and proliferation ascribed to CXCR7 need to be further rigorously confirmed.

This review focuses on discoveries related to endogenous and exogenous ligands for CXCR7. Some of them exclusively bind to CXCR7 while others have additional target receptors apart from CXCR7. Although all these ligands can bind to CXCR7, they can trigger totally different functional outcomes, with additional complexity of tissue-biased signaling as well. These aspects of consideration may explain why the contradicting opinions of CXCR7 exist. We will also emphasize the main disease relevance of CXCR7 and the therapeutic prospects CXCR7 may offer.

Pharmacological Ligands of CXCR7
================================

Endogenous Ligands for CXCR7
----------------------------

### SDF-1(CXCL12)

Stromal-cell derived factor (SDF-1), also known as CXCL12, is a pleiotropic chemokine ([@B74]) widely expressed among different organs including bone marrow, liver, heart, kidney, thymus, stomach, lymph nodes, pituitary gland, and brain ([@B62]). Beyond these, CXCL12 may be highly induced under certain pathological conditions including ischemia, inflammation, hypoxia, cancer, and autoimmune diseases ([@B78]; [@B65]). At first, CXCL12 was regarded as a soluble pre-B-cell growth stimulating factor (PBSF) which facilitates progenitor proliferation of bone marrow B cells ([@B100]), and later on its interaction with CXCR4 was discovered ([@B10]). More recently, research found that CXCL12 can take part in homing of progenitor leukocytes into the bone marrow microenvironment and adaptive immune processes ([@B61]; [@B101]).

Initially, CXCR4 was thought to be the exclusive receptor for CXCL12. Later on, CXCR7 was found to be a second receptor for CXCL12 at a 10-fold higher binding affinity compared to CXCR4 ([@B7]). The signaling activity of CXCL12 is crucial in neural, vascular, and cardiac development and craniofacial organogenesis. When binding to CXCR4, CXCL12 changes its three-dimensional conformation and initiates exchanging from GTP to GDP and dissociates into α- and βγ-subunits, then activates several cell signaling pathways ([@B6]). Through modulating adenylyl cyclase activity, the α~i~ subunits inhibit cAMP formation; and the βγ subunits can activate PLC-β, which in turn hydrolyzes PIP2 (phosphatidylinositol 4, 5-bisphosphate) facilitating the production of DAG (diacylglycerol) and IP3 (inositol) 1, 4, 5 triphosphate. These secondary messengers lead to release of Ca^2+^ from ER and activate protein kinase C. CXCL12 can activate PI3K (phosphoinositide 3-kinase)/Akt, IP3, and MAPK (mitogen activated protein kinase) through CXCR4 to regulate cell survival, chemotaxis, and proliferation. In addition, CXCL12 also activates JNK and p38 to control cell survival ([@B106]; [@B83]; [@B131]). In our lab we found that CXCR7 was expressed in macrophage-positive area of aortic atheroma of ApoE-null mice, but not in healthy arteries. Consistent with this, we found that during monocyte-to-macrophage differentiation process, CXCR7 was dramatically induced both at mRNA and protein levels. This CXCR7 induction prompted a CXCL12 signaling switch from pro-survival pathways (AKT and ERK1/2) to pro-inflammatory pathways (p38 and JNK), leading to increased macrophage phagocytosis ([@B141]).

At one point CXCR7 was regarded as a scavenger or decoy receptor for CXCL12. The original *in vivo* findings in zebrafish indicate that CXCR7 functions primarily by sequestering CXCL12, leading to a CXCL12 gradient formation ([@B13]). It was also shown in mice that CXCR7 appears to function as a scavenger receptor for CXCL12 to limit B cells in the splenic marginal zone ([@B138]). Consistent with this, although binding with CXCR7, CXCL12 is not able to mediate calcium mobilization ([@B154]). Besides, β-arrestin is more likely to be activated by CXCL12 ([@B111]). Sometimes CXCR4 and CXCR7 form heterodimers, in which case the conformation of CXCR4/G-protein complexes are changed by CXCR7 and thus its signaling capacity will be blocked ([@B77]). It should be noted, however, that such a negative impact of CXCR7 on CXCR4 was only observed on cell lines with ectopically over-expressed receptors and it remains to be determined whether the same is true on the native CXCR4 and CXCR7 receptors. The formation of CXCR4-CXCR7 heterodimers can also enhance CXCL12-induced intracellular Ca^2+^ mobilization and ERK1/2 activation ([@B121]). Through activation by CXCL12, the CXCR4--CXCR7 complex increases cell signaling by recruiting β-arrestin, including the ERK1/2 and p-38 pathways ([@B33]; [@B55]). Apart from these, other studies found that CXCR7 can independently mediate CXCL12-induced AKT and ERK activation via G-protein ([@B105]) or by β-arrestin ([@B48]; [@B111]).

### I-TAC (CXCL11)

IFN-inducible T cell α-chemoattractant (I-TAC), also termed CXCL11, is mainly expressed in the pancreas, peripheral blood leukocytes, thymus, liver, spleen, and lung. To a lesser degree, it is expressed in the prostate, placenta, and intestine ([@B24]). Just like CXCL12, CXCL11, binds to two chemokine receptors CXCR3 and CXCR7. Interferons have the ability to induce CXCL11 production among several cell lines including leukocytes, endothelial cells, and fibroblasts. The level of CXCL11 is up-regulated during an infection or cancer process. There are two variants of CXCR3: CXCR3-A and CXCR3-B. When binding with CXCR3-A or CXCR7, CXCL11 was found to promote cell proliferative signaling. In contrast, it inhibits the effect on cell growth while binding to CXCR3-B ([@B73]). The role of CXCR3 in metastasis seems far more complex because of the two isoforms CXCR3-A and CXCR3-B. Similar to CXCR4, CXCR3-A activates Gi protein and regulates its metastatic effects ([@B145]). In contrast, CXCR3-B recruits Gs instead of Gi and inhibits metastatic signals. Both high expression of CXCR3-A and downregulation of inhibitory signals via CXCR3-B contribute to prostate cancer cell migration and invasion. This implies that CXCL11 may bind to CXCR3-A and activate its downstream cascades and also suppress the expression level of CXCR3-B. Although no papers clearly mentioned interactions between CXCR3-A/B and CXCR7, such a possibility of a crosstalk between CXCR3-A/B and CXCR7 in tumor migration and invasion process remains to be determined. Similar to CXCL12, when binding with CXCR7, CXCL11 is not able to induce calcium signaling or activate ERK1/2 or AKT ([@B108]). However, some studies have demonstrated that CXCL11 can promote ERK and AKT phosphorylations in CXCR4^+^CXCR7^+^CXCR3^-^ cell lines ([@B130]). The contradictory results may have been because of the different cell lines used (tissue specific biased signaling). Furthermore, binding of CXCL11 to CXCR7 also recruits β-arrestin-2 which indicates that subsequent signaling is regulated by β-arrestin. Further studies of CXCL11 and CXCR7 interactions are needed to clarify these issues.

### MIF (Macrophage Inhibitory Factor)

Macrophage inhibitory factor acts as a pro-inflammatory cytokine with chemokine-like functions which regulate innate immunity. Originally, it was regarded as a T-cell derived factor which plays a role in inhibiting macrophage migration ([@B30]). It is widely expressed by several cells including eosinophils ([@B115]), endothelial cells ([@B104]), epithelial cells ([@B60]), lymphocytes ([@B5]), and macrophages ([@B18]). Under the dysregulated conditions, MIF participates in a series of diseases including rheumatoid arthritis, systemic lupus erythematosus, sepsis, glomerulonephritis, atherosclerosis, and cancer ([@B99]; [@B72]; [@B159]; [@B148]).

Several receptors have been shown to mediate MIF functions. The first is CD (cluster of differentiation) 74. CD74 is a single-pass type II transmembrane protein which is also known as the plasma membrane form of the major histocompatibility class II invariant chain (Ii) ([@B76]). Binding to CD74 mainly mediates survival and proliferative functions of MIF on immune and tumor cells. With the help of co-receptor CD44, MIF can induce signaling through CD74 to activate tyrosine kinases and the PI3K/AKT pathway ([@B120]; [@B88]). There is also evidence that MIF interacts with CD74 and subsequently activates ERK1/2 pathways ([@B120]). Apart from CD74, MIF is also identified as a non-cognate ligand for two chemokine receptors, CXCR2 and CXCR4, which regulate cell signaling through their cognate ligands CXCL1/CXCL8 and CXCL12, respectively. CXCR2 and CD74 can form heterodimers which is very important in MIF-regulated atherogenic leukocyte recruitment ([@B8]). Besides, CXCR4/CD74 complexes are able to activate the AKT pathway through interaction with MIF ([@B118]). Interestingly, signaling pathways and pathogenic effects which are regulated by MIF have been found recently to be linked with CXCR7. Both MIF-CXCR4 and MIF-CXCR7 axis play an important role in Rhabdomyosarcoma tumor cell migration. Furthermore, in platelets, MIF is able to activate AKT signaling pathway through CXCR7 to limit apoptosis ([@B129]; [@B20]). In addition to these, MIF is also found to promote CXCR7 internalization, induce B-cell chemotaxis, and ERK1/2 activation ([@B1]). These discoveries indicate that CXCR7 is a new receptor for MIF.

### ADM (Adrenomedullin)

As a peptide, ADM was first identified as a potent vasodilator ([@B68]). ADM is a mitogenic hormone with 52 amino acids which plays a crucial role in lymphatic vascular and cardiac development ([@B19]; [@B39]; [@B41]). It can activate cognate receptors consisting of CLR (calcitonin receptor-like receptor) and RAMP (receptor activity-modifying protein). There is also evidence that CXCR7 is able to bind to ADM with a *K*~d~ of 1.9 × 10^-7^ M ([@B64]). A recent study proved that the genetically overexpressed ADM ligand caused hypertrophic heart development during embryogenesis in Adm^hi/hi^ mice ([@B142]). In keeping with the crucial role of ADM in promoting lymph-angiogenesis, it was discovered that CXCR7^-/-^ presented lymphatic vascular defects. Based on their findings, the investigators suggested that CXCR7 acts as a decoy receptor for ADM in controlling cardiac and lymphatic development ([@B70]), a new mechanism that may explain the earlier findings by others in the field ([@B39]; [@B41]; [@B66]; [@B58]). Whether or not ADM can induce any signaling transduction through CXCR7 needs to be determined by further studies.

### BAM22 (Bovine Adrenal Medulla 22)

As one of the cleaved products of proenkephalin A, BAM22 was initially isolated from the bovine adrenal medulla ([@B96]; [@B35]). In mammals, BAM22 is widely distributed in the central nervous system ([@B67]; [@B107]). BAM22 has the classical opioid YGGFM motif and exerts both opioid and non-opioid actions ([@B12]). Through activating three major opioid receptors, μ-, δ-, and κ- ([@B42]; [@B110]; [@B75]), BAM22 not only inhibits contractions of ileum ([@B31]), vas deferens ([@B116]), and bladder ([@B36]), but also induces nociceptive response ([@B57]), which is sensitive to naloxone, a medication used to block the effects of opioids. It is quite important that as a unique endogenous peptide, BAM22 exhibits a high affinity when binding to the human Mas oncogene-related gene (Mrg) receptors, which are restricted to small-diameter DRG neurons in humans and rodents ([@B34]; [@B75]). Research has proven that altered BAM22 expression in DRG or spinal dorsal horn in complete Freund's adjuvant (CFA)-induced chronic pain and morphine tolerance which suggested that BAM22 participates in the nociceptive process ([@B17]; [@B21]). Recently it was found that CXCR7 is a high-affinity receptor for BAM22 which promoted glucocorticoid secretion. BAM22 can recruit both β-arrestin1 and β-arrestin2 at nanomolar concentrations after binding with CXCR7. Consistent with previous studies of CXCR7, BAM22 elicited neither a cyclic AMP (cAMP) nor a calcium response in H295R cells and human 293T cells, both of which express high levels of CXCR7. Intriguingly, the interaction between BAM22 and CXCR7 is also insensitive to naloxone ([@B59]). Further studies on possible cell signaling transduction between BAM22 and CXCR7 need to be explored.

### vCCL2/vMIP-II

Viruses are grouped into different families such as herpesviruses, retroviruses, and poxviruses. These pathogens encode chemokine-binding proteins, chemokine receptors, and chemokine analogs that hijack cellular chemokine receptors ([@B2]; [@B137]). Human herpesvirus 8 (HHV-8), also called Kaposi's sarcoma-associated herpesvirus (KSHV), is a good example. HHV-8 can lead to Kaposi's sarcoma (KS) which is closely related to immunodeficiency. It can also cause two rare proliferative disorders-primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD).

vCCL2, also known as vMIP-II, is a viral CC chemokine encoded by HHV-8. This chemokine was first discovered from the HHV-8 genome which was isolated from a KS biopsy ([@B103]). Three of the ORFs in HHV-8 were predicted to encode the chemokine homologs including vCCL1 (vMIP-I), vCCL2 (vMIP-II), and vCCL3 (vMIP-III), respectively, plus one CXC chemokine receptor homolog ORF74 ([@B98]). vCCL2 yields in a mature format as a 70-aa chemokine (7.9 kDa), and its 94-aa precursor endows a 23-aa N-terminal signal peptide and a C-terminal arginine ([@B98]; [@B69]).

As an active chemokine, vCCL2 is able to bind with four classes of receptors. They include CC family: CCR1, CCR2, CCR3, CCR5, CCR8, CCR10; XC family: XCR1; CX3C family: CX3CR1; and CXC family: CXCR4 ([@B90]; [@B109]; [@B125]). In addition, it has the ability to downregulate the activity of ORF74 ([@B44]). In most cases, vCCL2 is regarded as an antagonist chemokine whereas it can also act as agonist toward CCR3 and CCR8 ([@B125]). One thing noteworthy is that recently vCCL2 was found to act as a partial agonist of CXCR7 which can induce β-arrestin recruitment to the receptor. vCCL2 triggers MAP kinase and PI3K/AKT signaling through other chemokine receptors which can be reduced by CXCR7 expression ([@B126]). This study provided new insights into the interaction between viral chemokines and ACKRs like CXCR7.

Exogenous/Synthetic Ligands for CXCR7
-------------------------------------

### VUF11207 and VUF11403

From a styrene-amide scaffold, 24 derivatives were synthesized. These CXCR7 ligands were evaluated with pK~i~ values ranging from 5.3 to 8.1. With the help of SAR studies, two key compounds, VUF11207 and VUF11403, were found to have high affinity with CXCR7. These two CXCR7 agonists are able to recruit β-arrestin2 and reduce CXCR7 surface expression. Taken together, these two ligands have great value in CXCR7 study ([@B143]).

### AMD3100

AMD3100 is a small molecule which belongs to the bicyclam family. Initially AMD3100 was found to have antiretroviral effects and later on was shown to bind with CXCR4. Through interaction with CXCR4, AMD3100 shows strong and selective inhibitory effects of X4-tropic HIV replication *in vitro* ([@B32]). *In vivo*, the anti-HIV effect of AMD3100 was proved in the immunodeficiency (SCID)-Hu Thy/Liv mouse model ([@B29]). Based on these properties, AMD3100 is widely used as a tool for demonstrating the interaction between CXCL12 and CXCR4. As CXCR4 plays an important role during the hematopoietic stem cell homing process, singly administrated high doses of AMD3100 caused a huge release of these cells into peripheral blood. Thus, AMD3100 and its derivatives are undergoing testing for treatment of cancer ([@B32]).

Using a homodimeric receptor BRET sensor, researchers also found AMD3100 to be a ligand for CXCR7. Different from the antagonism effect on CXCR4, AMD3100 enhances CXCL12 binding with CXCR7. In addition, AMD3100 alone is able to recruit β-arrestin to CXCR7 but inhibits recruiting to CXCR4. Thus, AMD3100 is regarded as an agonist for CXCR7, albeit at relatively high concentrations (≥10 μM) ([@B63]).

### TC14012

TC14012 was modified from the parental entity TC140 which is a peptidomimetic derived from horseshoe crab polyphemusin and described as an inverse agonist of CXCR4 ([@B128]; [@B133]). TC14012, as a serum-stable compound, is able to recruit β-arrestin 2 to CXCR7 ([@B127]). Compared to AMD3100, TC14012 showed much higher potency with CXCR7 (EC~50~ of 350 nM for TC14012 vs. 140 μM for AMD3100) and only one log unit weaker than the natural ligand CXCL12 (35 nM) ([@B48]). Significant similarities were evident between the binding mode of TC14012 to CXCR7 and CVX15 to CXCR4 ([@B144]), which provided new insight into the interaction between TC14012 and CXCR7. Thus, TC14012 can be a helpful tool for studying the biology and pharmacology of CXCR7; however, it should be noted that TC14012 has antagonistic activity on CXCR4 as well, which complicates data interpretation when it is used for mechanistic study.

### CCX771

CCX771 is a selective small molecule agonist and binds to human CXCR7 with an IC~50~ of 4.1 nM. It was patented by ChemoCentryx and has not been commercially available ([@B154]). It has been reported that CCX771 is highly selective for CXCR7 and had no effect on CXCL12 binding to CXCR4 in NC-37 tumor cells ([@B154]). At present, CCX771 is often used in researches for studying the role of CXCR7 in different cell lines and animal models. For instance, CCX771 was able to inhibit tumor growth, lung metastasis, and tumor angiogenesis *in vivo*. This helped researchers unveiling that CXCL12-CXCR7 autocrine loop affects tumor endothelial cells proangiogenic properties ([@B149]). However, it remains uncertain whether many of the observed effects of CCX771 treatment is due to its agonistic activity on CXCR7 or its antagonistic effect on endogenous agonists such as CXCL12.

### Other Synthetic Ligands for CXCR7

Although no specific name was offered, Boehm et al recently reported a macrocyclic peptide-peptoid hybrid molecule, which binds to CXCR7 with high affinity (*K*~i~ \< 100 nM) and measurable passive permeability (*P*~app~ \> 5 × 10^-6^ cm/s). The bioactive peptide 25 (*K*~i~ = 9 nM) achieved oral bioavailability of 18% in rats, which was commensurate with the observed plasma clearance values upon intravenous administration ([@B11]). In addition, FC313, a cyclic pentapeptide ligand for CXCR7, which is modified at the I-Pro position with a bulky hydrophobic side chain, exhibited an improved bioactivity toward CXCR7 ([@B119]). Most recently, [@B3] reported a chimeric chemokine, which selectively binds to CXCR7. This chimera is composed of the N-terminus of CXCL11 and the main body and C-terminus of CXCL12 and selectively interacts with CXCR7 with high affinity, while not interfering with binding of CXCL11 and CXCL12 to their cognate receptors ([@B3]). We believe that all these newly generated ligands will be valuable pharmacologic tools for the study of CXCR7.

Major Disease Relevance for CXCR7
=================================

Cancers
-------

The expression levels of CXCL12 and its receptors were described in several types of solid tumors and tumor cells, including lung, prostate, breast, and pancreatic cancers ([@B71]; [@B139]; [@B146]; [@B147]). The particular microenvironment of tumors controls CXCR7 expression. For instance, under hypoxic conditions, the transcription level of CXCR7 in human microvascular endothelial cells and the translation level of CXCR7 in glioma cell lines were increased ([@B117]; [@B40]). Consistently, results showed that hypoxia-inducible factor 1 alpha leads to up-regulated CXCR7 transcript in mesenchymal stem cells ([@B84]). Tumor suppressor genes are silenced when DNA is methylated, thus there is evidence that the transcriptional level of CXCR7 is regulated by a cancer 1 (HIC1) tumor suppressor ([@B135]). For example, in prostate cancer cells, HIC1 negatively regulated the CXCR7 promoter ([@B156]). The expression level of CXCR7 is controlled by miRNA-430 in zebrafish which suggests that the overexpression of CXCR7 is caused by a lack of miRNA-mediated regulation ([@B123]). Consistent with this, downregulation of miRNA-430 induced a high expression level of CXCR7 in a bladder cancer cell line ([@B85]). In addition, the restoration of an important tumor-suppressive miRNA named miRNA-101, inhibited CXCR7 protein synthesis in normal hepatocyte-derived cell lines, different hepatocellular carcinoma cell lines, primary hepatocytes and xenograft mice models ([@B140]). Furthermore, [@B87] recently reported that in oral tongue squamous cell carcinoma, CXC chemokine-7 produced an inhibitory effect in cell growth and migration, which is mediated by epithelial to mesenchymal transition (EMT) signaling pathway. This implicates CXCR7 as a promising biomarker for chemokine receptor-based drug development ([@B87]).

Many tumor cells have the ability to produce CXCL12, whose extracellular bioavailability can be modulated by the cell-surface expressed CXCR4 and CXCR7. This was proved in *in vivo* imaging which showed that tumor cells expressing CXCR7 decreased the concentration of CXCL12 in the primary tumor microenvironment ([@B89]). Monomeric or dimeric forms of CXCL12 can make significant differences. Among different types of cancers, the dimeric form of CXCL12 can produce opposite effects. For instance, the dimeric CXCL12 is more potent than monomeric CXCL12 in promoting β-arrestin 2 recruitment and chemoattractive activity in a model of human breast cancer ([@B112]). In contrast, when it moved to a human colon carcinoma cell line, CXCL12 induced calcium mobilization, β-arrestin 2 recruitment, and cell migration from monomeric form whereas it only weakly induced chemotaxis and β-arrestin 2 recruitment ([@B37]). The differences between monomeric and dimeric CXCL12 forms are still not clear enough for unquestionable conclusions.

Depending on different tumor types, CXCR7 may or may not co-express with CXCR4. These two receptors can be distinctively expressed in glioma and breast cancer ([@B53]; [@B89]). In contrast, CXCR7 and CXCR4 often co-express in human pancreatic cancer tissues ([@B55]). The single expression of these two receptors on certain cell populations restricts their ability for paracrine regulation. By comparison, co-expression of these two receptors on the same cell population made the direct interaction between CXCR4 and CXCR7 and controlled signaling pathways reciprocally possible.

The CXCL12-mediated chemotactic function was changed when both CXCR4 and CXCR7 expressed on the same cell line. For instance, when CXCR7 was transfected into breast cancer cell line MDA-MB-231, the CXCL12-induced chemotactic function was increased ([@B33]). Also, under the condition of upregulated CXCR4 expression, CXCR7 enhanced cell chemotaxis in response to CXCL12 in rat mammary adenocarcinoma cell line MTLn3 ([@B56]). However, it was also shown that CXCR7 limited chemotaxis effects through the interaction of CXCR4 and CXCL12 in human neuroblastoma cell lines ([@B80]).

The key element for promoting angiogenesis and malignant cell migration is the distribution of endothelial progenitor cells (EPCs), which is controlled by trans-endothelial migration. Since CXCR7 is highly expressed on EPCs, it determines the survival effect of CXCL12 on EPCs. In addition, CXCR7 also influences these CXCL12-regulated processes including trans-endothelial migration, proliferation, adhesion, and tube formation of EPCs ([@B27]). The increased expression of CXCR7 is beneficial for angiogenesis in cancers which indicates the key role of CXCR7 in controlling the angiogenic process. Under hypoxic conditions, CXCL8 and VEGF were highly increased in the tumor microenvironment, which amplifies CXCR7 expression through the positive feedback mechanism ([@B122]). In breast cancer, CXCR7 activation promotes primary tumor growth through increasing VEGF production and microvessel density ([@B56]). When applied to osteosarcoma and associated lung metastasis, the evidence that CXCR7 is significantly expressed on tumor-associated vessels confirmed its critical role in the metastatic process ([@B46]). In hepatocellular carcinoma, CXCR7 is able to enhance endothelial cell proliferation, migration, and VEGF production which mediate angiogenesis and tumor growth ([@B157]). In a nut shell, CXCR7 seems very important for angiogenesis and metastasis in tumor cells.

Despite the accumulating evidence, whether the binding of CXCL12 to CXCR7 can directly induce cell migration is still in debate, so in non-small lung cancer cells, CXCR7 has not been conclusively implicated in CXCL12-regulated behavior ([@B23]). However, the CXCL12 effects regulated through CXCR4 for promoting metastasis can be affected by CXCR7. Under certain conditions, CXCR7 has the ability to impair CXCR4-regulated effects. In breast cancer derived from an immune-deficient mouse model, CXCR7 prevented tumor cell invasion and spontaneous lung metastasis formation ([@B56]). Also, the interaction between CXCL12 and CXCR7 did influence CXCR4-mediated trans-endothelial migration of human tumor cells ([@B154], [@B153]). On the contrary, the activation of CXCR7 was able to promote metastasis in the breast cancer model ([@B95]). The role of CXCR7 in tumor migration is still not conclusive and further studies on its role with CXCR4 are needed.

The discovery of CXCR7 has provided human beings a viable target for anti-tumor and anti-metastatic drugs. Using the model of mice engrafted with breast and lung cancer cell lines, inhibiting CXCR7 with believed antagonists showed that CXCR7 is able to promote tumor growth ([@B95]). The main purpose for developing CXCR7 antagonists is to decrease the spreading of tumor cells, their metastasis, and angiogenesis. As an example, CCX771, a synthetic CXCR7 antagonist, showed high potential of inhibiting trans-endothelial migration as compared to AMD3100, a CXCR4 antagonist. However, in a lymphoblastic leukemia model, CCX771 also recruited β-arrestin to CXCR7 ([@B154]). Thus, whether CCX771 should be considered as an antagonist or agonist, needs to be further explored. This is an important question when considering CXCR7 as a target for cancer treatment. On the other hand, it was shown that both CXCR4 and CXCR7 responded to CXCL12 to greatly increase human lymphoma cells' migration, indicating that CXCR7 might be an efficient target for cancer treatment ([@B153]).

Since the expression of CXCR7 may be able to direct hematopoietic stem cells (HSCs) to the niches which sustain their migration capacity, CXCR7 is a potential regulatory target for HSCs mobilization-inducing agent development. This is supported by an *in vitro* study indicating that although CXCR7 is not an intrinsic signaling receptor for CXCL12 on CD34^+^ HSCs, its blocking can be useful for therapeutic interference with CXCR4-mediated activation of integrins and cell adhesion ([@B52]). In addition, a recent *in vivo* study provided further evidence indicating that CXCR7 contributes to homing of acute myeloid leukemia and normal CD34^+^ progenitor cells to the bone marrow and spleen of NOD/SCID mice ([@B94]); however, further mechanistic study is needed to fully understand the role of CXCR7 in HSCs. Although the ability of CXCR7 to regulate the BMSC niche is still in debate, studying CXCR7 antagonists is a hot spot among HSCs mobilizers because this may provide patients with an alternative treatment when other mobilization protocols fail ([@B132]).

The structural model for CXCR7 is very helpful for elucidating the pharmacology and potential therapeutic utility of CXCR7 antagonists. Unfortunately, there are no detailed structures available at present and only a limited number of ligands for CXCR7 have been reported ([@B63]; [@B143]; [@B97]). Therefore, approaches such as virtual screening and GPCR homology modeling which have been used in the previous studies of CXCR4 can be promising tools for new CXCR7 ligand identification ([@B151]). A number of pharmacological studies focus on the small molecules of CXCR7 antagonists. These antagonists endow reasonable affinities but researchers lack structural information ([@B16]; [@B154]; [@B53]; [@B26]). The synthetic, modeling, and pharmacological effect on small molecules targeting CXCR7 was described in a recent report ([@B143]).

The molecules which can block CXCR4 and CXCR7 simultaneously, represent an ideal pharmacological approach because both receptors are involved in cancer malignancy and GBM angiogenesis ([@B38]). However, the current available data governing the binding of these two receptors seems rather complex. Some antagonists did not bind to CXCR4 or CXCR7 exclusively, but bound to the other one, too. And even when they didn't act as antagonist, partial agonist activity did show up. This happened on AMD3100, a CXCR4 antagonist which may also act as a CXCR7 partial agonist ([@B63]). In addition, the expression levels of CXCR4 were down-regulated through CXCR7 agonists which selectively activated β-arrestin ([@B134]). These complex biological responses may be due to cell type specific biased signaling. For GBM, CXCR4 was mainly expressed in CSCs whereas CXCR7 is mainly distributed in differentiated cells and endothelia ([@B53]; [@B43]). In other situations these two receptors are often co-expressed and could potentially form heterodimers. Thus the study of ligands which can interact with both CXCR4 and CXCR7 must be evaluated in specific cell type while considering agonist/antagonist properties of the molecule. Blocking both CXCR4 and CXCR7 through influencing their shared ligands will help researchers better understand the interaction mode between the ligands and the CXCR4/CXCR7 receptors. Synthetic compounds derived from the family of chalcones, have high affinity binding with CXCL12 and can prevent CXCL12 from interacting with CXCR4 and CXCR7. Such a process is able to inhibit inflammatory responses in eosinophils ([@B50]). In addition, there is an RNA oligonucleotide named NOX-A12 which can bind and neutralize CXCL12 with high affinity ([@B79]). Because of the antitumor activity, NOX-A12 is now clinically available for treatment of leukemia and multiple myeloma. It is also noteworthy that, in an *in vivo* model of GBM, NOX-A12 was effective in inhibiting or delaying recurrences following irradiation ([@B86]).

Cardiovascular Diseases
-----------------------

CXCR7 is expressed in the developing heart and associated with defects in the cardiovascular system. Knocking out *CXCR7* gene can lead to a phenotype of hypertrophy including thickened pulmonary, aortic valves, and partially overridden aortas ([@B121]; [@B45]; [@B152]). These abnormalities may have a relationship with disturbed endothelial cell migration because those hypertrophic defects were reproduced in endothelial cell specific CXCR7 knockout mice ([@B121]). CXCR7 was regarded as a scavenger receptor for CXCL12 in heart valves, so one proposed hypothesis is that CXCR7 prevents the over-interaction between CXCL12 and CXCR4 through sequestering CXCL12 during heart development, which could lead to hyperplasia ([@B102]). However, at this point, we could not rule out the possibility that CXCR7 may independently transduce cell signaling in some vascular cells. On this aspect, CXCL12-CXCR4 axis is credited with controlling the migration and proliferation of EPCs whereas CXCL12-CXCR7 mainly maintains the survival of EPCs and promotes these cells adhering to endothelial cells ([@B150]). It is also important to note that, CXCR7 can transduce cell signaling through β-arrestin to promote the migration of vascular smooth muscle cells ([@B111]), strengthening the viewpoint of the importance of possible biased signaling on CXCR7. The formation of a CXCR4--CXCR7 heterodimer indicates that these two receptors may have mutual functions during angiogenesis. Either deletion of CXCR4 or CXCR7 leads to ventricular septum defects, showing that these two receptors are potential new intervention targets for studying certain cardiovascular diseases ([@B158]; [@B121]). Again, it should be noted that whether the natural CXCR4 and CXCR7 receptors form heterodimers needs to be further investigated, since such heterodimers having enhanced responses to CXCL12 was observed only in HEK293 cells with overexpressed CXCR4 and CXCR7 ([@B121]).

The pivotal role of CXCL12 in the cardiovascular system makes itself and its receptors a hotspot of cardiovascular disease research. During the past few years, scientists focused on the CXCL12-CXCR4 axis in myocardial infarction and heart ischemia whereas very few studies mentioned the function of CXCR7. Of the few studies available, one study discovered that CXCL12-β protects cardiac cells via CXCR7 ([@B155]) and evidence implied that CXCR7 signaling is able to take part in the regeneration process after myocardial infarction ([@B121]; [@B150]). In addition, it was found that lack of endothelial CXCR7 impairs vascular homeostasis and cardiac remodeling after myocardial infarction. This indicated that CXCR7 might be a potential therapeutic target for certain cardiovascular diseases, such as restenosis ([@B51]). CXCR7 also produces beneficial effects on angiogenic function of EPCs, which are mediated predominantly by a protein kinase B/glycogen synthase kinase-3β/Fyn pathway via increased activity of Nrf2 ([@B28]). Further, it seems that CXCR7 expression is also critical for limiting endothelial-to-mesenchymal transition and pulmonary fibrosis ([@B49]). Since we recently reported that during monocyte-to-macrophage differentiation, CXCR7 is dramatically induced and mediates CXCL12 signaling independent of CXCR4, which leads to increased macrophage phagocytosis ([@B91]). Furthermore, we reported that CXCR7 induction is suppressed by atorvastatin treatment, leading to decreased macrophagemigration in response to CXCL12 ([@B92]). Collectively, these findings highlight that CXCR7 may be a new therapeutic target for cardiovascular diseases, such as atherosclerosis.

Conclusion and Perspectives
===========================

The axis of CXCL12-CXCR4 plays a very important role in physiology and pathology, and the discovery of CXCR7 as a new high affinity receptor for CXCL12 made this interaction system much more sophisticated. Previous studies mainly focused on the triangle relationship of CXCL12, CXCR4, and CXCR7, while other ligands for CXCR7 have been ignored. CXCR7 itself can play multiple roles with its endogenous and exogenous ligands. It may just act as a rheostat for certain ligands through scavenging them and not transducing any cell signaling pathways. It may also act as a co-factor to dimerize with other receptors in cell signaling transduction. In addition, CXCR7 may independently induce cell signaling transduction, either through G protein or β-arrestin, or other unknown transducer, depending on the cell types or different stages of cell differentiation. We are just discovering the tip of the iceberg of the biased signaling network system for CXCR7 and its ligands in various cell types. More interesting and vital connections are emerging from study of the massive iceberg that is CXCR7.
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